JP2023550311A5 - - Google Patents

Info

Publication number
JP2023550311A5
JP2023550311A5 JP2023528113A JP2023528113A JP2023550311A5 JP 2023550311 A5 JP2023550311 A5 JP 2023550311A5 JP 2023528113 A JP2023528113 A JP 2023528113A JP 2023528113 A JP2023528113 A JP 2023528113A JP 2023550311 A5 JP2023550311 A5 JP 2023550311A5
Authority
JP
Japan
Prior art keywords
month
antibody
individual
pharmaceutical composition
cycles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/072193 external-priority patent/WO2022099257A1/en
Publication of JP2023550311A publication Critical patent/JP2023550311A/ja
Publication of JP2023550311A5 publication Critical patent/JP2023550311A5/ja
Pending legal-status Critical Current

Links

JP2023528113A 2020-11-03 2021-11-02 多発性骨髄腫の処置のための、イサツキシマブの使用 Pending JP2023550311A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063109305P 2020-11-03 2020-11-03
US63/109,305 2020-11-03
US202163239108P 2021-08-31 2021-08-31
US63/239,108 2021-08-31
PCT/US2021/072193 WO2022099257A1 (en) 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
JP2023550311A JP2023550311A (ja) 2023-12-01
JP2023550311A5 true JP2023550311A5 (cg-RX-API-DMAC7.html) 2024-11-13

Family

ID=78825149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528113A Pending JP2023550311A (ja) 2020-11-03 2021-11-02 多発性骨髄腫の処置のための、イサツキシマブの使用

Country Status (8)

Country Link
US (1) US20220135696A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240416A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023550311A (cg-RX-API-DMAC7.html)
AU (1) AU2021376374A1 (cg-RX-API-DMAC7.html)
CA (1) CA3197381A1 (cg-RX-API-DMAC7.html)
IL (1) IL302640A (cg-RX-API-DMAC7.html)
TW (1) TW202233235A (cg-RX-API-DMAC7.html)
WO (1) WO2022099257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
MX2020007429A (es) * 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
IL285110B2 (en) * 2019-01-28 2025-11-01 Sanofi Sa Methods of treating multiple myeloma
US20200330594A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
CN120501855A (zh) * 2019-05-14 2025-08-19 赛诺菲-安万特美国有限责任公司 给予抗cd38抗体以治疗多发性骨髓瘤的方法

Similar Documents

Publication Publication Date Title
JP2023517236A5 (cg-RX-API-DMAC7.html)
JP2014114288A5 (cg-RX-API-DMAC7.html)
JP2023541860A5 (cg-RX-API-DMAC7.html)
JP2023542290A5 (cg-RX-API-DMAC7.html)
JP2011506483A5 (cg-RX-API-DMAC7.html)
JP2019523295A5 (cg-RX-API-DMAC7.html)
JP2023524149A5 (cg-RX-API-DMAC7.html)
JP2023542289A5 (cg-RX-API-DMAC7.html)
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2020536097A5 (cg-RX-API-DMAC7.html)
JP2013543501A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2021523122A5 (cg-RX-API-DMAC7.html)
JP2023542257A5 (cg-RX-API-DMAC7.html)
JP2023541858A5 (cg-RX-API-DMAC7.html)
JP2023551559A5 (cg-RX-API-DMAC7.html)
JP2023542092A5 (cg-RX-API-DMAC7.html)
JP2023542291A5 (cg-RX-API-DMAC7.html)
RU2014117510A (ru) Лечение ревматоидного артрита
JP2023520771A5 (cg-RX-API-DMAC7.html)
JP2022513386A5 (cg-RX-API-DMAC7.html)
JP2018535961A5 (cg-RX-API-DMAC7.html)
JP2023515675A5 (cg-RX-API-DMAC7.html)
JP2025514978A5 (cg-RX-API-DMAC7.html)
JP2023510199A5 (cg-RX-API-DMAC7.html)